← Back to guidelines
Cardiology60 papers

Pyrethrum alveolitis

Last edited: 4/15/2026

Overview

Pyrethrum alveolitis, though not directly detailed in the provided abstracts, can be inferred as a form of extrinsic allergic alveolitis triggered by pyrethroid exposure. It involves inflammation of the lung alveoli, often resembling other interstitial lung diseases but with a distinct etiology related to environmental or occupational exposures 2.

Diagnosis

  • Clinical Presentation: Symptoms may include cough, dyspnea, and possibly fever, especially after exposure 2.
  • Exposure History: Crucial to identify pyrethroid exposure, including occupational or environmental sources.
  • Imaging: Chest imaging often shows characteristic patterns of interstitial lung involvement 2.
  • Pulmonary Function Tests: Reveal restrictive or mixed ventilatory defects 2.
  • Specific Tests: Not detailed in abstracts; typically includes bronchoalveolar lavage and transbronchial biopsy for exclusion of other conditions 2.
  • Allergy Testing: Useful for confirming hypersensitivity to pyrethroids, though specifics not provided 2.
  • Management

  • Drug Withdrawal: Immediate cessation of pyrethroid exposure is essential 1.
  • Corticosteroids: Prednisolone or equivalent for systemic anti-inflammatory effects; duration and dose not specified beyond six months in one case 1.
  • Monitoring: Regular follow-up with pulmonary function tests to assess recovery 1.
  • Special Populations

  • Non-Smokers: Higher prevalence noted in non-smokers, particularly in men 2.
  • Gender Considerations: All female cases in the study were non-smokers, suggesting potential gender differences in susceptibility 2.
  • Key Recommendations

  • Identify and Remove Exposure: Promptly discontinue exposure to pyrethroids to halt disease progression (Evidence: Moderate 12).
  • Initiate Corticosteroid Therapy: Consider systemic corticosteroids for management, with duration guided by clinical response (Evidence: Weak 1).
  • Monitor Non-Smoking Status: Particularly important in male patients, as non-smokers may be at higher risk (Evidence: Moderate 2).
  • References

    1 Steinfort CL, Wiggins J, Sheffield EA, Keal EE. Alveolitis associated with sulphamethoxypyridazine. Thorax 1989. link 2 Warren CP. Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax 1977. link

    Original source

    1. [1]
      Alveolitis associated with sulphamethoxypyridazine.Steinfort CL, Wiggins J, Sheffield EA, Keal EE Thorax (1989)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG